FT: Goldman Sach's investment arm agrees €2bn deal for drugmaker Synthon

Goldman Sachs Asset Management has agreed a more than €2bn deal to acquire drugmaker Synthon from BC Partners, according to people familiar with the matter, as it hopes to capitalise on demand for off-patent versions of complex medicines.

Private equity group BC Partners, which acquired a majority stake in the business in 2019 at an enterprise value of €750mn, will retain a roughly 25 per cent stake in the group after the Goldman Sachs deal, one of the people said.

The sale of Synthon by BC Partners takes the investment group’s exited positions to about €13bn in the past 18 months.

Read more here in the Financial Times.